Form 4: Spero Therapeutics Director John C. Pottage Jr. Receives 20,000 Restricted Stock Units

Spero Therapeutics, Inc. Director John C. Pottage Jr. was granted 20,000 restricted stock units (RSUs) as part of his compensation, vesting in June 2026.

Summary

• John C. Pottage Jr., a Director of Spero Therapeutics, Inc. (SPRO), reported the acquisition of 20,000 shares of common stock.
• The transaction occurred on June 12, 2025, and was classified as an acquisition (A) with a price of $0.00 per share.
• These 20,000 shares consist of restricted stock units (RSUs), where each RSU represents the right to receive one share of common stock upon vesting.
• The RSUs are scheduled to vest on June 12, 2026, contingent upon Mr. Pottage Jr.'s continued service to the company.
• Following this transaction, John C. Pottage Jr. directly beneficially owns a total of 75,000 shares of Spero Therapeutics, Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates continued director involvement and alignment of interests through equity compensation, which is a standard and expected practice.

Positives

• The grant of restricted stock units to a director aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• The continued service requirement for vesting indicates a commitment from the director to the company's long-term success.

Future Outlook

The document does not provide a general future outlook for the company, focusing solely on an insider equity transaction.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across various industries, including biotechnology, to incentivize and retain key personnel by aligning their financial interests with company performance.

Related Party Transactions

• The acquisition of 20,000 restricted stock units by Director John C. Pottage Jr. from Spero Therapeutics, Inc. constitutes a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be viewed positively as it aligns the director's financial interests with the long-term performance of the company's stock, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The 20,000 restricted stock units are scheduled to vest on June 12, 2026, contingent on the director's continued service.

Key Dates

Keywords

Spero Therapeutics, SPRO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership